

Table SV. Treatment and follow up of the 12 chronic spontaneous urticaria (CSU) patients with serum samples collected in the remission phase

Case	Sex	Age, years	Disease duration, months	Therapeutic regimens	Refractory	Time interval (m)	Outcome
1	F	39	5	2-fold dose	No	12.3	Medication withdrawal for 8 months
2	F	52	3	2-fold equivalent dose	No	15.2	Medication withdrawal for 3 months
3	F	33	2	4-fold equivalent dose and montelukast and ranitidine	Yes	20.3	Medication withdrawal for 6 months
4	F	49	4	4-fold equivalent dose	Yes	4.5	Fexofenadine 120 mg once daily
5	M	30	2	4-fold equivalent dose and ranitidine	Yes	5.9	Olopatadine 5 mg once daily, ranitidine 350 mg twice daily
6	F	31	5	3-fold equivalent dose	No	6.3	Licensed dose
7	F	41	6	2-fold dose	No	6.5	Licensed dose
8	F	32	3	4-fold equivalent dose	Yes	8.4	Licensed dose
9	M	27	4	4-fold equivalent dose and ranitidine	Yes	8.6	Licensed dose
10	F	30	2	4-fold equivalent dose and ranitidine and TGP	Yes	10.3	Licensed dose
11	F	35	12	4-fold equivalent dose	Yes	18.9	Licensed dose
12	M	33	3	4-fold dose	Yes	21.5	Licensed dose

Time interval: refers to the time interval between two time point of serum collections; TGP: total glucosides of peony.